mFOLFOX6与XELOX方案治疗转移性结肠癌的疗效及对患者肿瘤标志物水平的影响  

Effect of mFOLFOX6 and XELOX regimens in the treatment of metastatic colon cancer and their impact on patient tumor markers

作　　者：江静 侯俊明 肖刚 JIANG Jing;HOU Junming;XIAO Gang(Department of Medical Oncology,Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,Shaanxi,China)

机构地区：[1]陕西中医药大学附属医院肿瘤内科,陕西咸阳7120000

出　　处：《癌症进展》2023年第20期2239-2241,2272,共4页Oncology Progress

基　　金：陕西省中医药管理局科研项目(2021-ZZ-LC012)。

摘　　要：目的探讨5-氟尿嘧啶+亚叶酸钙+奥沙利铂(mFOLFOX6)方案与奥沙利铂+卡培他滨(XELOX)方案治疗转移性结肠癌的疗效及对患者肿瘤标志物[血清铁蛋白(SF)、结肠癌转移相关基因1(MACC1)、核苷酸切除修复交叉互补基因1(ERCC1)]水平的影响。方法依据治疗方式的不同将124例转移性结肠癌患者分为对照组(n=59)和观察组(n=65),对照组患者给予mFOLFOX6方案化疗,观察组患者给予XELOX方案化疗。比较两组患者的临床疗效、血清肿瘤标志物水平及不良反应发生情况。结果观察组患者的治疗总有效率为66.15%,与对照组患者的54.24%比较,差异无统计学意义(P﹥0.05)。治疗后,两组患者SF、MACC1、ERCC1水平均低于本组治疗前,观察组患者SF、MACC1、ERCC1水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者骨髓抑制发生率比较,差异无统计学意义(P﹥0.05);观察组患者胃肠道反应、肝肾功能损伤、口腔黏膜炎发生率均低于对照组,差异均有统计学意义(P﹤0.05)。结论mFOLFOX6与XELOX方案治疗转移性结肠癌的疗效相当,但XELOX方案在降低患者肿瘤标志物水平方面更具优势,且安全性较高。Objective To investigate the effect of 5-fluorouracil+calcium folinate+oxaliplatin(mFOLFOX6)regimen and oxaliplatin+capecitabine(XELOX)regimen in the treatment of metastatic colon cancer and their impact on patient tumor markers[serum ferritin(SF),metastasis associated in colon cancer 1(MACC1),excision repair cross-complementation group 1(ERCC1)].Method A total of 124 patients with metastatic colon cancer were divided into control group(n=59)and observation group(n=65)according to different treatment methods.Patients in the control group were given mFOLFOX6 regimen chemotherapy,and patients in the observation group were given XELOX regimen chemotherapy.The clinical efficacy,serum tumor marker levels,and occurrence of adverse events were compared between the two groups.Result The total effective rate of treatment in the observation group was 66.15%,the difference was not statistically significant compared with 54.24%in the control group(P>0.05).After treatment,the levels of SF,MACC1,and ERCC1 in both groups were lower than those before treatment,the levels of the foregoing indicators in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of bone marrow suppression between the two groups(P>0.05).The incidence rates of gastrointestinal reactions,liver and kidney function damage,and oral mucositis in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion The XELOX regimen could achieve comparable efficacy to mFOLFOX6 in the treatment of metastatic colon cancer,and the XELOX regimen has more advantages in reducing tumor marker levels with high safety.

关 键 词：mFOLFOX6方案 XELOX方案 转移性结肠癌 血清铁蛋白 结肠癌转移相关基因1 核苷酸切除修复交叉互补基因1 

分 类 号：R735.35[医药卫生—肿瘤]